Prediction Case File
YouTubeEvaluation Complete

Hims Stock: The Turnaround Is Only Beginning!

1 extracted signal · 1 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
18 Jun 2026, 19:04 UTC
Recorded by Tahlil Plus
18 Jun 2026, 19:12 UTC
Video preview for Hims Stock: The Turnaround Is Only Beginning!
Source overview

AI-generated source summary

Barclays has raised its price target for Hims & Hers Health (HIMS) from $29 to $39, maintaining an overweight rating. This adjustment is supported by the company's significant revenue growth and improving Adjusted EBITDA margins, which are projected to reach 11% by FY 2026. The company's strategic investments and M&A activities, particularly in international markets like Canada and Australia, are expected to drive further growth. HIMS's strategy of acquiring and integrating telehealth companies and expanding into new service areas such as weight loss, sexual health, dermatology, and mental health, positions it to capture a substantial share of the growing telehealth market. The company's financial outlook indicates a strong growth trajectory, with projected revenues of $6.5 billion+ and Adjusted EBITDA of $1.3 billion+ by 2030. The valuation metrics, such as the EV/Sales ratio, are considered attractive at around 2.4x, suggesting significant upside potential.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
1
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Source processing completed

    Source analysis and structured extraction completed.

  5. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  6. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  7. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
355
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail